Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06885073 · ClinicalTrials.gov registry record · NA
Non-invasive Central Venous Pressure Estimation in Pediatric Patients
A NA study of Central Venous Pressure, sponsored by Compremium.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06885073 is a NA study of Central Venous Pressure that is actively recruiting participants, run by Compremium. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06885073, a NA study of Central Venous Pressure, is actively recruiting participants, sponsored by Compremium.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Central Venous Pressure (CVP) is a standard parameter for hemodynamic monitoring and is currently measured through the insertion of a catheter. The pediatric population is especially vulnerable to risks associated to this invasive procedure, including infection, thrombosis, and pneumothorax. The proposed pilot study will evaluate safety and preliminary efficacy of a new non-invasive ultrasound-based venous occlusion pressure (VOP) monitoring device (CPMX2) in children equipped with an invasive catheter for CVP monitoring as part of standard of care.
Conditions Studied
Interventions
- DEVICE CPMX2
Study Locations (1)
District of Columbia
- Children's National Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06885073
The ClinicalTrials.gov registry entry for NCT06885073 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Compremium, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Venous Pressure appearing as the primary indexed condition, and to 1 intervention - of which CPMX2 is the first listed.
NCT06885073 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06885073 about?
NCT06885073 is a clinical study titled "Non-invasive Central Venous Pressure Estimation in Pediatric Patients". Central Venous Pressure (CVP) is a standard parameter for hemodynamic monitoring and is currently measured through the insertion of a catheter. The pediatric population is especially vulnerable to risks associated to this invasive procedure, including infection, thrombosis, and pneumothorax. The pro...
What is the current status of trial NCT06885073?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-03-10. Estimated completion is 2026-03-31.
What conditions does trial NCT06885073 study?
This clinical trial studies the following conditions: Central Venous Pressure.
What interventions are being tested in trial NCT06885073?
The interventions under investigation include: CPMX2 (DEVICE).
Who is sponsoring clinical trial NCT06885073?
This trial is sponsored by Compremium, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06885073 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.